Plain-English translation of NCT07298395 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a new medication called can help adults with moderate to severe atopic dermatitis (eczema). About half of participants will receive the medication daily for 12 weeks, while the other half will receive a placebo (inactive pill) to compare results. The study will measure whether the medication reduces itching, redness, and the area of skin affected by eczema.
Many people with moderate to severe eczema don't respond well to current treatments like topical creams and steroids, or they can't tolerate them. This trial is testing whether this new medication could offer a better option for people whose eczema isn't adequately controlled with existing treatments.
You likely qualify if…
You likely don't qualify if…
You will visit the clinic every 2 to 4 weeks for 12 weeks, then return for a final visit around week 16. At each visit, the research team will examine your skin and run tests to track how your eczema is changing. You'll take either the new medication or a placebo once daily at home, and keep a simple diary noting when you take your pill and how your skin feels.
AI-generated summary from trial data · Oct 5, 2026 · Not medical advice
United States